Saturday 17 October 2026
Export MGNX’s income statement to Excel — free account
MacroGenics, Inc.
MGNX Healthcare Biotechnology
In the quarter to June 2026, revenue grew 378.0%, EPS grew 154.4% and free cash flow grew 12.9%, each against the same quarter a year earlier.
3.25
0.12
−3.56%
Follow MGNX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 3 | 2 | 5 | 2 | 5 | 5 | 2 | 5 | 2 |
P/S ratio |
0.68 | 1.36 | 10.73 | 2.57 | 12.42 | 11.43 | 8.15 | 8.65 | 4.44 | 7.48 |
Altman Z-Score |
(6.01) | (5.50) | (3.60) | (3.82) | 0.94 | 5.79 | 0.04 | 0.66 | 5.44 | 9.34 |
Altman Z″-Score (non-manufacturers) |
(12.89) | (12.52) | (10.44) | (10.48) | (6.89) | (0.68) | (3.47) | (1.29) | 5.87 | 7.68 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
2.36 | (5.30) | (22.49) | 13.33 | (17.72) | (216.67) | (13.75) | (19.09) | 6.27 | (24.27) |
Beneish M-Score |
(0.22) | (1.78) | (2.61) | (0.03) | (4.33) | (2.03) | (1.94) | 1.90 | (0.84) | 0.08 |
P/B ratio |
1.83 | 1.75 | 4.13 | 2.75 | 4.02 | 4.05 | 2.27 | 2.14 | 2.34 | 2.56 |
Price to Tangible BV |
1.83 | 1.75 | 4.13 | 2.75 | 4.02 | 4.05 | 2.27 | 2.14 | 2.34 | 2.56 |
EV/Sales |
(0.55) | 0.05 | 6.93 | 1.60 | 9.36 | 8.89 | 4.89 | 4.88 | 2.55 | 4.54 |
EV/EBITDA |
1.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
1.01 | (0.12) | (5.20) | (2.79) | (5.04) | (8.33) | (2.34) | (1.91) | 27.92 | (9.54) |
EV/FCF |
0.99 | (0.11) | (5.09) | (2.68) | (4.83) | (7.92) | (2.26) | (1.65) | (26.82) | (7.57) |
Quick Ratio |
4.72 | 3.71 | 4.28 | 4.33 | 3.41 | 5.83 | 5.06 | 4.38 | 6.41 | 10.25 |
Current Ratio |
5.10 | 3.92 | 4.48 | 4.57 | 3.75 | 6.17 | 5.31 | 4.49 | 6.48 | 10.40 |
Net Debt/EBITDA |
2.82 | 1.91 | 1.40 | 1.41 | 1.28 | 2.28 | 1.30 | 1.43 | 20.46 | 5.28 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.58 | 0.54 | 0.20 | 0.49 | 0.22 | 0.30 | 0.20 | 0.17 | 0.46 | 0.27 |
Operating CF/Net income |
1.09 | 1.02 | 8.63 | 0.73 | 0.71 | 0.86 | 0.88 | 0.89 | (0.73) | 0.75 |
Capex/Depreciation |
(0.34) | (0.75) | (0.37) | (0.30) | (0.48) | (0.50) | (0.40) | (3.01) | (4.07) | (1.50) |
Interest Coverage |
(8.56) | (99.17) | (117.65) | (71.42) | (101.40) | (163.82) | (52.11) | (74.44) | — | — |
| (86.95%) | (49.85%) | (6.15%) | (62.76%) | (75.49%) | (49.28%) | (64.12%) | (63.25%) | (6.91%) | (20.11%) | |
| (28.78%) | (23.91%) | (3.13%) | (38.90%) | (56.62%) | (37.54%) | (47.10%) | (48.57%) | (5.73%) | (17.46%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (350.76%) | (744.62%) | (1,068.54%) | 0.00% | 0.00% |
Return on Tangible Assets |
(39.39%) | (37.19%) | (4.17%) | (58.95%) | (83.29%) | (42.66%) | (62.52%) | (64.48%) | (6.09%) | (21.31%) |
Average Days of Receivables |
32.65 | 10.49 | 64.41 | 135.06 | 48.95 | 80.32 | 72.47 | 179.60 | 31.57 | 10.98 |
Research and Development Expense of Revenue |
98.44% | 118.16% | 283.55% | 136.25% | 277.06% | 184.21% | 304.28% | 317.40% | 93.34% | 132.88% |
Selling, General and Administrative Expense of Revenue |
26.19% | 47.38% | 88.83% | 38.80% | 81.36% | 40.75% | 71.76% | 67.36% | 20.70% | 32.47% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
9.56% | 19.63% | 31.27% | 13.45% | 29.86% | 19.71% | 30.49% | 27.48% | 9.35% | 13.24% |
Graham Net Nets |
0.18 | 0.35 | 0.17 | 0.21 | 0.19 | 0.19 | 0.30 | 0.35 | 0.35 | 0.35 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(72.67%) | (33.23%) | (1.47%) | (30.50%) | (21.00%) | (10.89%) | (29.14%) | (33.39%) | (3.24%) | (8.48%) |
Free Cash Flow Yield |
(81.57%) | (35.34%) | (12.67%) | (23.18%) | (15.59%) | (9.83%) | (26.49%) | (34.28%) | (2.14%) | (8.01%) |
Revenue per Share |
2.37 | 2.39 | 0.95 | 2.47 | 1.29 | 2.00 | 1.33 | 1.47 | 4.37 | 2.65 |
Operating CF per Share |
(1.28) | (1.09) | (1.26) | (1.42) | (2.40) | (2.13) | (2.79) | (3.74) | 0.40 | (1.26) |
Capex per Share |
(0.03) | (0.06) | (0.03) | (0.06) | (0.10) | (0.11) | (0.09) | (0.61) | (0.81) | (0.33) |
Free Cash Flow per Share |
(1.31) | (1.15) | (1.29) | (1.47) | (2.50) | (2.25) | (2.88) | (4.35) | (0.42) | (1.59) |
Cash per Share |
3.01 | 3.22 | 3.71 | 2.51 | 4.06 | 5.20 | 4.49 | 5.69 | 8.45 | 7.99 |
Shareholders Equity per Share |
0.88 | 1.85 | 2.46 | 2.31 | 4.00 | 5.64 | 4.80 | 5.93 | 8.29 | 7.75 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.88 | 1.85 | 2.46 | 2.31 | 4.00 | 5.64 | 4.80 | 5.93 | 8.29 | 7.75 |
Free Cash Flow |
(82.94) | (71.92) | (79.90) | (90.58) | (150.03) | (117.80) | (138.56) | (178.19) | (15.00) | (55.06) |
Working Capital |
176.83 | 161.96 | 195.23 | 173.57 | 204.98 | 261.92 | 194.62 | 209.18 | 272.54 | 256.65 |
Capital Expenditures |
(1.90) | (3.55) | (1.70) | (3.62) | (6.20) | (5.91) | (4.29) | (24.95) | (29.40) | (11.38) |
Net Current Asset Value |
18.69 | 71.89 | 105.53 | 83.73 | 183.93 | 229.74 | 157.91 | 179.87 | 247.65 | 241.44 |
EV/EBIT |
1.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.02 | 0.03 | 0.02 | 0.08 | 0.06 | 0.07 | 0.42 | 0.19 | 0.12 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.44 | 0.26 | 0.21 | 0.41 | 0.34 | 0.28 | 0.22 | 0.15 | 0.14 | 0.42 |
Cash ROIC |
(33.78%) | (22.64%) | (20.89%) | (30.56%) | (31.05%) | (20.72%) | (31.04%) | (37.45%) | (2.48%) | (10.09%) |
Accounts Receivable Turnover |
16.91 | 20.44 | 1.76 | 4.56 | 4.63 | 5.86 | 3.03 | 2.78 | 19.23 | 46.08 |
Accounts Payable Turnover |
7.35 | 2.15 | 1.45 | 0.72 | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
7.89 | 0.00 | 6.15 | 2.53 | 0.00 | — | — | — | — | — |
Average Days of Payables |
48.52 | 148.77 | 286.02 | 242.16 | 2,134.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
80.18 | 0.00 | 54.20 | 71.72 | 604.16 | — | — | — | — | — |
Average Receivables |
8.84 | 7.34 | 33.29 | 33.30 | 16.73 | 17.91 | 21.16 | 21.61 | 8.20 | 1.99 |
Average Payables |
4.90 | 5.73 | 5.67 | 10.20 | 11.77 | 6.17 | 4.16 | 3.23 | 3.22 | 3.48 |
Average Inventory |
4.57 | — | 1.34 | 2.92 | — | — | — | — | — | — |
Average Assets |
259.25 | 280.04 | 289.44 | 307.86 | 356.99 | 345.62 | 322.32 | 353.01 | 342.57 | 335.27 |
Average Common Equity |
85.82 | 134.34 | 147.31 | 190.82 | 267.75 | 263.26 | 236.75 | 271.06 | 283.99 | 291.04 |
Columns are period end dates